AstraZeneca to sublicense global Movantik rights to RedHill Biopharma
LONDON: AstraZeneca Plc has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). RedHill will make an upfront payment of $52.5 million to AstraZeneca on closing and a further non-contingent payment…